Details for New Drug Application (NDA): 011325
✉ Email this page to a colleague
NDA 011325 describes VESPRIN, which is a drug marketed by Apothecon and Bristol Myers Squibb and is included in three NDAs. Additional details are available on the VESPRIN profile page.
The generic ingredient in VESPRIN is triflupromazine. There are two drug master file entries for this compound. Additional details are available on the triflupromazine profile page.
The generic ingredient in VESPRIN is triflupromazine. There are two drug master file entries for this compound. Additional details are available on the triflupromazine profile page.
Summary for 011325
| Tradename: | VESPRIN |
| Applicant: | Apothecon |
| Ingredient: | triflupromazine hydrochloride |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 20MG/ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 004
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 10MG/ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 005
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 3MG/ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
